Cara Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020
August 03 2020 - 4:01PM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company
focused on developing and commercializing new chemical entities
designed to alleviate pruritus by selectively targeting peripheral
kappa opioid receptors, or KORs, today announced that the Company
will host a conference call and live audio webcast on Monday,
August 10, 2020, at 4:30 p.m. ET to report second quarter 2020
financial results and provide a corporate update.
To participate in the conference call, please dial (855)
445-2816 (domestic) or (484) 756-4300 (international) and refer to
conference ID 7669087. A live webcast of the call can be accessed
under “Events & Presentations” in the News & Investors
section of the Company’s website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara
website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company
focused on developing and commercializing new chemical entities
designed to alleviate pruritus by selectively targeting peripheral
kappa opioid receptors, or KORs. Cara is developing a novel and
proprietary class of product candidates, led by KORSUVA™
(CR845/difelikefalin), a first-in-class KOR agonist that targets
the body’s peripheral nervous system, as well as certain immune
cells. In two Phase 3 trials, KORSUVA Injection has demonstrated
statistically significant reductions in itch intensity and
concomitant improvement in quality of life measures in hemodialysis
patients with moderate-to-severe chronic kidney disease-associated
pruritus (CKD-aP). Cara has successfully completed its Phase 2
trial of Oral KORSUVA for the treatment of pruritus in patients
with CKD and is currently conducting Phase 2 trials of Oral KORSUVA
in atopic dermatitis and primary biliary cholangitis patients with
moderate-to-severe pruritus.
The FDA has conditionally accepted KORSUVA™ as the trade name
for difelikefalin injection. CR845/difelikefalin is an
investigational drug product and its safety and efficacy have not
been fully evaluated by any regulatory authority.
MEDIA CONTACT: Annie Starr 6 Degrees
973-415-8838 astarr@6degreespr.com
INVESTOR CONTACT: Janhavi Mohite Stern Investor
Relations, Inc. 212-362-1200Janhavi.Mohite@sternir.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024